US7759396B2 - Antineoplastic preparation and the use of antineoplastic preparation - Google Patents
Antineoplastic preparation and the use of antineoplastic preparation Download PDFInfo
- Publication number
- US7759396B2 US7759396B2 US11/813,526 US81352606A US7759396B2 US 7759396 B2 US7759396 B2 US 7759396B2 US 81352606 A US81352606 A US 81352606A US 7759396 B2 US7759396 B2 US 7759396B2
- Authority
- US
- United States
- Prior art keywords
- cells
- akg
- alpha
- glutamine
- ketoglutarate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related, expires
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- An object of the invention is antineoplastic preparation and the use of antineoplastic preparation.
- the antineoplastic preparation distinguishes itself in that it contains alpha-ketoglutarate (AKG) or/and glutamine or/and glutamate or/and alpha-ketoglutarate of ornithine or/and dipeptides of glutamine and other amino acids or/and tripeptides of glutamine and other amino acids or/and di- and tripeptides of glutamate with other amino acid or/and mono- and divalent metal salts and other of alpha-keto-glutarate or/and glutamine or/and glutamate or/and ornithine of alpha-ketoglutarate.
- AKG alpha-ketoglutarate
- antineoplastic preparation is that the preparation containing alpha-ketoglutarate (AKG) or/and glutamine or/and glutamate or/and alpha-ketoglutarate of ornithine or and dipeptides of glutamine and other amino acids or/and tripeptides of glutamine and other amino acids or/and di- and tripeptides of glutamate with other amino acid or/and mono- and divalent metal salts and other of alpha-keto-glutarate or/and glutamine or/and glutamate or/and ornithine or alpha-ketoglutarate is used in the prophylaxis of neoplastic diseases.
- AKG alpha-ketoglutarate
- antineoplastic preparation is that the preparation containing alpha-ketoglutarate (AKG) or/and glutamine or/and glutamate or/and alpha-ketoglutarate of ornithine or/and dipeptides of glutamine and other amino acids or/and tripeptides of glutamine and other amino acids or/and di- and tripeptides of glutamate with other amino acid or/and mono- and divalent metal salts and other of alpha-keto-glutarate or/and glutamine or/and glutamate or/and ornithine of alpha-keto-glutarate is used for metastases inhibition.
- alpha-ketoglutarate AKG
- the preparation and the use of the preparation allows for the inhibition of the migration of neoplastic cells reflecting the potential role of AKG in the metastases inhibition.
- the preparation added to the diet plays a role as neo-adjuvant supporting existing methods used in the neoplasm treatment. It may improve the quality of the a patient's life through the synergistic action with antineoplastic drugs and simultaneous protective activity to normal cells.
- FIG. 1 depicts a curve presenting the proliferation of A549 cells with the stimulation by AKG.
- FIG. 2 depicts the proliferation of C6 cells with AKG.
- FIG. 3 depicts the proliferation of HT-29 cells with AKG stimulation.
- FIG. 4 presents the proliferation of human neoplastic cells A549 in the presence of the cyclophosphamide with AKG.
- FIG. 5 depicts the proliferation of human neoplastic cells A549 in the presence of iphosphamide with AKG.
- FIG. 6 depicts the proliferation of human neoplastic cells A549 in the presence of thiotepa with AKG.
- FIG. 7 depicts the inhibition of C6 cells migration due to AKG.
- A549 human neoplastic cells of the lung cancer; the continuous line obtained from the Institute of the Immunology and the Experimental Therapy of Polish Academy of Science in Wroclaw.
- HT-29 human neoplastic cells of the large intestine cancer; the continuous line obtained from the Institute of the Immunology and the Experimental Therapy of Polish Academy of Science in Wroclaw.
- C6 the rat neoplastic cells of the brain cancer (glioma); the continuous line obtained from the Department of Neonatology, Humboldt University, Berlin, Germany.
- DMEM:F-12 HAM 2:1
- HT-29 and C6 cells on the basis DMEM.
- 10% foetal beast serum (FBS), penicillin 100 i.u./ml and streptomycin 100 ⁇ g/ml were added.
- the basis DMEM:F-12 HAM, DMEM was produced by Sigma company (Sigma, St. Louis, Mo., U.S.A.).
- the foetal beast serum (FBS) was produced by Life Technologies company (Life Technologies, Düsseldorf, Germany). Remaining reagents were produced by Sigma company.
- Cells stored in liquid nitrogen in a tissue bank were unfrozen at a temperature of 37° C., then poured into the plastic bottles containing the proper basis. They were cultured in a temperature of 37° C. in the incubator with 5% CO 2 flow. After the cells' reproduction liquid was poured out, the cells were washed with PBS (without the calcium and magnesium ions) and processed with 0.25% trypsin solution+EDTA to receive the suspension of cells necessary in the experience.
- MTT solution in PBS condition in concentration 5 mg/ml was added into each pit on a plastic plate in a dose of 15 ⁇ l/pit. Plates were incubated for 3 hours at a temperature of 37° C. Thereafter, buffer SDS-HCl in a does 100 ⁇ l/pit was added and the plates were left at a temperature of 37° C. all night. The results were evaluated next day with the use of E-max Reader (Molecular Devices Corporation, Menlo Park, Calif., U.S.A.).
- This method is for the estimation of the activity of substances affecting the mobility of cells in vitro. It is used in research on wounds healing, angiogenesis and neoplastic metastases.
- C6 cells (1 ⁇ 10 6 ) suspended in the culture basis with the addition of 10% serum (FBS) were poured onto the culture plates (NUNC, Roskilde, Denmark) with 4 cm diameter.
- FBS 10% serum
- the flaw (wound) was done with the ending of automatic pipette and unstuck cells were removed by twice-rinsing the plates with a PBS solution.
- AKG (10 and 20 mM) dissolved in the culture basis was added to the prepared culture. Plates were incubated for 24 hours in a temperature of 37° C. and in a humid atmosphere 95% air and 5% CO 2 . Thereafter the cultures were coloured with the May-Grünwald-Giemza method.
- Antiproliferative activity of AKG in the cultures was estimated in differen kinds of neoplastic cells: the lung cancer cells (A549), the large intestine cancer cells (HT-29) and glioma cells (C6). Cells were processed with AKG in concentrations 0.5, 1, 2.5, 5, 10 and 20 mM, for 96 hours.
- the examined substance has had antiproliferative activity with relation to all neoplastic cells types (see the diagram— FIG. 1 , FIG. 2 , FIG. 3 ).
- Statistically significant (4.5%) inhibition of cells' growth was observed at AKG concentration 2.5 mM in A549 cell line in the comparison to the control group. That effect was correlated with a dose of AKG and was 7.8%, 12.4%, 17.5% with doses 5 mM, 10 mM and 20 mM respectively (see the diagram on FIG. 1 ).
- the growth inhibition in glioma cells (C6) was 12.6% with AKG dose 2.5 mM, 7.9%—5 mM, 16%—10 mM and 19.8%—20 mM, respectively.
- AKG increased its cytostatic activity by 6.4%, 9.8% and 14.4% respectively (the diagram— FIG. 4 ).
- Iphosphamid 1.5 mM inhibited the cells growth by 7.3%.
- AKG addition (5, 10 and 20 mM) that effect increased by 5%, 5.3% and 8.8% respectively (the diagram— FIG. 5 ).
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL372183 | 2005-01-11 | ||
PL372183A PL372183A1 (pl) | 2005-01-11 | 2005-01-11 | Preparat przeciwnowotworowy oraz zastosowanie preparatu przeciwnowotworowego |
PLP372183 | 2005-01-11 | ||
PCT/PL2006/000003 WO2006075924A1 (en) | 2005-01-11 | 2006-01-10 | Antineoplastic preparation and the use of antineoplastic preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
US20080058422A1 US20080058422A1 (en) | 2008-03-06 |
US7759396B2 true US7759396B2 (en) | 2010-07-20 |
Family
ID=36168380
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/813,526 Expired - Fee Related US7759396B2 (en) | 2005-01-11 | 2006-01-10 | Antineoplastic preparation and the use of antineoplastic preparation |
Country Status (12)
Country | Link |
---|---|
US (1) | US7759396B2 (pl) |
EP (1) | EP1845966B1 (pl) |
JP (2) | JP2008526838A (pl) |
CN (1) | CN101111241B (pl) |
AT (1) | ATE474570T1 (pl) |
AU (1) | AU2006205279B2 (pl) |
CA (1) | CA2593780C (pl) |
DE (1) | DE602006015608D1 (pl) |
DK (1) | DK1845966T3 (pl) |
ES (1) | ES2349233T3 (pl) |
PL (2) | PL372183A1 (pl) |
WO (1) | WO2006075924A1 (pl) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2033623A1 (en) * | 2007-09-07 | 2009-03-11 | Cutech S.R.L. | Compositions comprising ornithine ketoglutarate (OKG) |
WO2015123229A1 (en) * | 2014-02-12 | 2015-08-20 | The Regents Of The University Of California | Compositions and methods for treating aging and age-related diseases and symptoms |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5006551A (en) | 1988-02-03 | 1991-04-09 | Leopold & Co., Chem. Pharm. Fabrik Aktiengesellschaft | Composition for destroying malignant tumors |
US6429229B1 (en) * | 1998-03-13 | 2002-08-06 | Chiesi S.A. | Keto acid salts and amine derivatives, and their use for preparing medicines |
WO2004012662A2 (en) | 2002-08-01 | 2004-02-12 | Aesgen, Inc. | Improved treatment of cancer with glutamine |
WO2004098619A2 (en) * | 2003-05-07 | 2004-11-18 | Osteologix A/S | Treating cartilage / bone conditions with water-soluble strontium salts |
US20040259766A1 (en) * | 2001-11-23 | 2004-12-23 | Tadeusz Studzinski | Use of glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof for the manufacture of a composition for the treatment of osteoporosis |
WO2006066244A2 (en) | 2004-12-17 | 2006-06-22 | Cash Alan B | Method for extending lifespan and delaying the onset of age-related disease |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT412447B (de) * | 2002-11-27 | 2005-03-25 | C Y L Handelsges M B H | Mittel mit zerstörender wirkung auf maligne tumore sowie verfahren zu seiner herstellung |
US20050124684A1 (en) * | 2003-08-29 | 2005-06-09 | Ying Du | 5-(hydroxymethyl) furfural and derivatives as inhibitors of TNFalpha and IL-1beta production |
-
2005
- 2005-01-11 PL PL372183A patent/PL372183A1/pl not_active Application Discontinuation
-
2006
- 2006-01-10 EP EP06700207A patent/EP1845966B1/en not_active Not-in-force
- 2006-01-10 US US11/813,526 patent/US7759396B2/en not_active Expired - Fee Related
- 2006-01-10 DE DE602006015608T patent/DE602006015608D1/de active Active
- 2006-01-10 JP JP2007550321A patent/JP2008526838A/ja not_active Ceased
- 2006-01-10 CN CN2006800019675A patent/CN101111241B/zh not_active Expired - Fee Related
- 2006-01-10 AU AU2006205279A patent/AU2006205279B2/en not_active Ceased
- 2006-01-10 AT AT06700207T patent/ATE474570T1/de not_active IP Right Cessation
- 2006-01-10 CA CA2593780A patent/CA2593780C/en not_active Expired - Fee Related
- 2006-01-10 WO PCT/PL2006/000003 patent/WO2006075924A1/en active Application Filing
- 2006-01-10 PL PL06700207T patent/PL1845966T3/pl unknown
- 2006-01-10 ES ES06700207T patent/ES2349233T3/es active Active
- 2006-01-10 DK DK06700207.1T patent/DK1845966T3/da active
-
2012
- 2012-10-01 JP JP2012219701A patent/JP2013035864A/ja active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5006551A (en) | 1988-02-03 | 1991-04-09 | Leopold & Co., Chem. Pharm. Fabrik Aktiengesellschaft | Composition for destroying malignant tumors |
US6429229B1 (en) * | 1998-03-13 | 2002-08-06 | Chiesi S.A. | Keto acid salts and amine derivatives, and their use for preparing medicines |
US20040259766A1 (en) * | 2001-11-23 | 2004-12-23 | Tadeusz Studzinski | Use of glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof for the manufacture of a composition for the treatment of osteoporosis |
WO2004012662A2 (en) | 2002-08-01 | 2004-02-12 | Aesgen, Inc. | Improved treatment of cancer with glutamine |
WO2004098619A2 (en) * | 2003-05-07 | 2004-11-18 | Osteologix A/S | Treating cartilage / bone conditions with water-soluble strontium salts |
WO2006066244A2 (en) | 2004-12-17 | 2006-06-22 | Cash Alan B | Method for extending lifespan and delaying the onset of age-related disease |
Non-Patent Citations (1)
Title |
---|
Robinson et al. Amino acid nutrition and immune function in tumour-bearing rats . . . Clinical Science. 1999, vol. 97, pp. 657-669. * |
Also Published As
Publication number | Publication date |
---|---|
CA2593780C (en) | 2013-11-26 |
CN101111241A (zh) | 2008-01-23 |
EP1845966B1 (en) | 2010-07-21 |
JP2013035864A (ja) | 2013-02-21 |
PL1845966T3 (pl) | 2011-02-28 |
WO2006075924A1 (en) | 2006-07-20 |
ATE474570T1 (de) | 2010-08-15 |
CA2593780A1 (en) | 2006-07-20 |
EP1845966A1 (en) | 2007-10-24 |
ES2349233T3 (es) | 2010-12-29 |
JP2008526838A (ja) | 2008-07-24 |
AU2006205279B2 (en) | 2011-05-26 |
AU2006205279A1 (en) | 2006-07-20 |
PL372183A1 (pl) | 2006-07-24 |
US20080058422A1 (en) | 2008-03-06 |
CN101111241B (zh) | 2010-12-01 |
DE602006015608D1 (de) | 2010-09-02 |
DK1845966T3 (da) | 2010-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6255347B1 (en) | Methods and compositions comprising R-ibuprofen | |
Kawaratani et al. | Therapeutic strategies for alcoholic liver disease: Focusing on inflammation and fibrosis | |
CN110062621B (zh) | 氨基酸组合物及其用途 | |
Zhang et al. | Effect of hydrogen-rich water on acute peritonitis of rat models | |
US20210030703A1 (en) | Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers | |
WO1997048391A9 (en) | Methods and compositions comprising r-ibuprofen | |
Zhou et al. | Hydrolyzed wheat gluten alleviates deoxynivalenol-induced intestinal injury by promoting intestinal stem cell proliferation and differentiation via upregulation of Wnt/β-catenin signaling in mice | |
US20180140596A1 (en) | New Pharmaceutical use and Pharmaceutical composition of pyrroloquinoline quinine, its derivatives and/or its salts | |
CN101014330A (zh) | 2,5-二羟基苯磺酸在制备可应用于治疗血管依赖型疾病诸如癌症和银屑病的药物中的应用 | |
JP2021529736A (ja) | 炎症の軽減又は治療のための組成物及び方法 | |
US7759396B2 (en) | Antineoplastic preparation and the use of antineoplastic preparation | |
JP2021527669A (ja) | 線維症の軽減又は治療のための組成物及び方法 | |
JP2012232982A (ja) | 動物の体重および大きさをグリシンで調節する方法 | |
Hossain et al. | N-Myc knockdown and apigenin treatment controlled growth of malignant neuroblastoma cells having N-Myc amplification | |
US20110105617A1 (en) | Method for treatment of neoplastic diseases with alpha-keto glutarate and/or salts thereof | |
Kleinerman et al. | Effect of L-phenylalanine mustard, adriamycin, actinomycin D, and 4′-(9-acridinylamino) methanesulfon-m-anisidide on naturally occurring human spontaneous monocyte-mediated cytotoxicity | |
Elsakkar et al. | Sodium valproate, a histone deacetylase inhibitor, with praziquantel ameliorates Schistosoma mansoni-induced liver fibrosis in mice | |
US20200261393A1 (en) | Treatment of cancer with combinations of agents | |
JP6811983B2 (ja) | 網膜神経節細胞死抑制活性を有する経口用組成物 | |
WO2005023368A1 (en) | Prophylaxis of and treatment for infections from the family chlamydiaceae using amino acids as leucine or methionine | |
WO2022080249A1 (ja) | 炎症性腸疾患の予防又は改善剤 | |
TWI722492B (zh) | 含蓮蓬萃取物之組合物及其用於治療頭頸癌症之用途 | |
Qi et al. | Porphyromonas gingivalis induces chronic kidney disease through crosstalk between the NF‑κB/NLRP3 pathway and ferroptosis in GMCs | |
CN117731651A (zh) | 蛋氨酸在制备治疗细菌感染性疾病的药物或抗生素增效剂中的应用 | |
CN115737645A (zh) | At56联合索拉非尼在外周t细胞淋巴瘤中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SGP & SONS AB, SWEDEN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PIERZYNOWSKI, STEFAN;KANDEFER-SZERSZEN, MARTYNA;RZESKI, WOJCIECH;REEL/FRAME:020002/0067;SIGNING DATES FROM 20070829 TO 20070903 Owner name: SGP & SONS AB, SWEDEN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PIERZYNOWSKI, STEFAN;KANDEFER-SZERSZEN, MARTYNA;RZESKI, WOJCIECH;SIGNING DATES FROM 20070829 TO 20070903;REEL/FRAME:020002/0067 |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.) |
|
LAPS | Lapse for failure to pay maintenance fees |
Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20180720 |